Posted on January 20, 20261/20/26
Navigating A New Era: Reflections on Canada’s Enhanced CDA-AMC Reimbursement Review Process
Posted on December 10, 202512/10/25
Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis
Posted on August 25, 20258/25/25
Evaluation of HTA Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access
Posted on April 11, 20254/11/25
Unlocking Pharma Success: Mike Ryan’s Pre-Conference Talk at Reuters Pharma 2025
Posted on April 10, 20254/10/25
Unlock the Power of Indirect Treatment Comparisons (ITC) with Industry Experts
Posted on February 27, 20252/27/25
Securing Launch Success Within the Context of the New EU Health Technology Assessment Regulation (HTAR) Landscape in Europe
Posted on March 27, 20243/27/24
Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur
Posted on October 17, 202310/17/23
Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)
Posted on August 1, 20238/1/23